GlaxoSmithKline
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 1929-01-01
- Employees
- 70.2K
- Market Cap
- $90B
- Website
- http://www.gsk.com
- Introduction
GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.
GSK's fully liquid Menveo meningococcal vaccine approved by European Commission
GSK's Menveo, a fully liquid MenACWY vaccine, received EC approval for use without reconstitution, aiding in the prevention of invasive meningococcal disease in children, adolescents, and adults.
GSK liquid meningitis vaccine gets EU approval
GSK announces EC approval of single-vial, fully liquid Menveo vaccine for invasive meningococcal disease caused by serogroups A, C, W, and Y, licensed for children from 2 years, adolescents, and adults. Based on Phase IIb trials, the liquid formulation shows comparable immunogenicity, tolerability, and safety to the existing lyophilised/liquid version.
GSK's Liquid Meningitis Vaccine Gets EU Authorization
GSK's liquid meningitis vaccine, Menveo, approved by the European Commission for sale in the EU, simplifying vaccination against invasive meningococcal disease without reconstitution, licensed for children from age two, adolescents, and adults.
Stock-exchange announcement
The article contains a PDF file with encoded data, including various symbols and characters that represent the content of the document.
Geographic Disparities in Gynecologic Oncology Clinical Trial Availability in the US
Study finds states with higher economic vulnerability and minoritized populations have fewer gynecological cancer trials per 100,000 persons, highlighting the need for efforts to address these disparities.
clinical trial genAI-powered control tower, Vivo, wins 1st place in the CNS ...
Vivo, developed by OmniScience, won the CNS Summit Innovation Showcase for its ability to streamline clinical trial data accessibility and support actionable insights. The platform's genAI capabilities enable teams to make informed decisions, reducing trial timelines and increasing success rates.
Alector stock drops after Alzheimer's drug fails in Phase II trial
Alector’s Phase II INVOKE-2 trial for Alzheimer’s therapy AL002 failed to meet primary endpoint, leading to discontinuation of long-term extension trial and 17% workforce reduction. The company plans to focus on monoclonal antibodies programs with GSK, including latozinemab for frontotemporal dementia and AL101 for early Alzheimer’s. Alector’s stock dropped 31% post-announcement.
Related Clinical Trials:
FDA Accepts BLA for Belantamab Mafodotin–Based Combos in R/R Myeloma
The FDA accepted a BLA for belantamab mafodotin combinations (BVd and BPd) in multiple myeloma, supported by DREAMM-7 and DREAMM-8 trials showing significant PFS improvements. The FDA target action date is July 23, 2025.
Related Clinical Trials:
© Copyright 2024. All Rights Reserved by MedPath